# nVision Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nvision-medical

- Industry: Medical Devices & Equipment
- Headquarters: San Bruno, US
- Website: www.nvisionmedical.com
- Total disclosed funding: $16M
- Latest round: Series B (Jul 28, 2016)
- Investors on record: 8

## About

nVision Medical Corp. is a medical technology company focused on developing innovative solutions for women's health, particularly in the field of gynecological diagnostics. Their advanced products aim to enhance patient outcomes and streamline healthcare processes.Founded in 2011, nVision Medical Corp. specializes in gynecological diagnostic solutions. The company is based in San Bruno, US and has undergone strategic pivots to focus on women's health innovations. Notably, in April 2018, Boston Scientific Corporation acquired nVision Medical Corp. for an initial USD 150 mn, with an additional USD 125 mn contingent on clinical and commercial milestones. The company has engaged in 5 total deals throughout its history.nVision Medical Corp. develops advanced diagnostic tools for gynecological health, focusing on improving women's healthcare outcomes. Their innovative products are designed to facilitate early detection and treatment options for a range of conditions, ensuring that healthcare providers have access to the latest technologies to support patient care.nVision Medical Corp. generates revenue through the sale of its medical devices and diagnostic solutions, primarily distributed to healthcare institutions. The company's pricing strategies reflect the specialized nature of its products, targeting hospitals and clinics dedicated to women's health.nVision Medical Corp. plans to leverage the recent acquisition by Boston Scientific to expand its product offerings and market reach. Upcoming innovations are expected to be launched in the next few years, focusing on enhanced diagnostics and treatment solutions for gynecological conditions. The company aims to enter new geographic markets, particularly in Europe and Asia, by 2025, utilizing funding from the recent acquisition to support research and development initiatives.

## Funding rounds

- Series B, Jul 28, 2016, $12M — Arboretum Ventures, Catalyst Health Ventures, Golden Seeds, Seraph Group, Life Science Angels, Inc., Draper, Astia Angels, LMN Ventures
- Series A, Jun 4, 2013, $4.2M — Catalyst Health Ventures, Golden Seeds, Seraph Group, Life Science Angels, Inc., Draper, Astia Angels, LMN Ventures
- Seed, Dec 13, 2011, $0.1M — Catalyst Health Ventures

## Investors

- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Seed, Series A, Series B
- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series A, Series B
- Seraph Group (https://capitalatlas.ai/funds/seraph-group) — Series A, Series B
- Life Science Angels, Inc. — Series A, Series B
- Draper (https://capitalatlas.ai/funds/draper) — Series A, Series B
- Astia Angels (https://capitalatlas.ai/funds/astia-angels) — Series A, Series B
- LMN Ventures (https://capitalatlas.ai/funds/lmn-ventures) — Series A, Series B
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series B